The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of KRAS mutational variant on response to immunotherapy in metastatic NSCLC.
 
Shelley Kuang
No Relationships to Disclose
 
Sally C. M. Lau
No Relationships to Disclose
 
Kieran Sharma
No Relationships to Disclose
 
Juehea Lee
No Relationships to Disclose
 
Malcolm Isaiah Ryan
No Relationships to Disclose
 
Sabine Schmid
Consulting or Advisory Role - Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); MSD (Inst); MSD (Inst); MSD (Inst); MSD (Inst)
Research Funding - AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst)
Travel, Accommodations, Expenses - Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; MSD; MSD; MSD; MSD; Takeda; Takeda; Takeda; Takeda
 
Penelope Ann Bradbury
Honoraria - Abbvie; Lilly; Merck
Consulting or Advisory Role - Abbvie; Boehringer Ingelheim
(OPTIONAL) Uncompensated Relationships - Abbvie; AstraZeneca
 
Geoffrey Liu
Honoraria - Abbvie; AstraZeneca; Bayer; Bristol-Myers Squibb; Merck; novartis; pfizer; Roche Canada; Takeda
Consulting or Advisory Role - AstraZeneca/MedImmune; novartis; pfizer; Roche Canada; takeda
Speakers' Bureau - AstraZeneca; Takeda
Research Funding - AstraZeneca/MedImmune (Inst); Boehringer Ingelheim; roche (Inst); Takeda
 
Frances A. Shepherd
Stock and Other Ownership Interests - AstraZeneca; Lilly
Honoraria - AstraZeneca; Daiichi Sankyo; Merck Serono; Takeda
Consulting or Advisory Role - AstraZeneca; Merck Serono
Research Funding - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Pfizer (Inst); Roche Canada (Inst)
 
Ming Sound Tsao
Consulting or Advisory Role - Amgen; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; Merck
Research Funding - AstraZeneca/MedImmune (Inst); Bayer (Inst)
 
Natasha B. Leighl
Honoraria - Boehringer Ingelheim
Consulting or Advisory Role - Xcovery
Research Funding - EMD Serono (Inst); Guardant Health (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Roche Canada (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; GlaxoSmithKline; Merck Sharp & Dohme; Nektar; Roche
 
Adrian G. Sacher
Honoraria - Amgen; AstraZeneca; Bayer; BMS; Genentech/Roche; KisoJi Biotechnology; Merck; Pfizer; Tesaro
Consulting or Advisory Role - Amgen; AstraZeneca/MedImmune; Bayer; BMS; Genentech/Roche; KisoJi Biotechnology; Merck; Pfizer
Research Funding - AstraZeneca; Genentech/Roche
Travel, Accommodations, Expenses - AstraZeneca; Genentech/Roche; GlaxoSmithKline; Gritstone Bio; Pfizer